Click on headlines below to download research

IRL757 progress prompts $2.5m milestone payment
IRLAB Therapeutics | 08/10/2024

IRLAB Therapeutics has announced that it will receive a $2.5m milestone payment from the McQuade Center for Strategic Research and Development (MSRD),…

...read more

IRL757 starts strong in Phase I
IRLAB Therapeutics | 03/10/2024

IRLAB Therapeutics has announced an encouraging update for the ongoing Phase I trial for IRL757, which is being developed as a potential treatment for…

...read more

Pirepemat Phase IIb trial completes enrolment
IRLAB Therapeutics | 01/10/2024

IRLAB Therapeutics has announced the completion of patient enrolment for the Phase IIb trial (React PD) assessing pirepemat’s ability to improve…

...read more